An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease.
Saved in:
| Title: | An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease. |
|---|---|
| Authors: | Miesbach, Wolfgang1 (AUTHOR) wolfgang.miesbach@kgu.de, Halimeh, Susan2 (AUTHOR), Platokouki, Helen3 (AUTHOR), Podolak‐Dawidziak, Maria4 (AUTHOR), Zdziarska, Joanna5 (AUTHOR), Korczowski, Bartosz6 (AUTHOR), Chowdary, Pratima7 (AUTHOR), Austin, Steve8 (AUTHOR), Millar, Carolyn9 (AUTHOR), Alamelu, Jayanthi10 (AUTHOR), Rogosch, Tobias11 (AUTHOR), Pabinger, Ingrid12 (AUTHOR) |
| Source: | Haemophilia. Jan2024, Vol. 30 Issue 1, p236-240. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
